Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks.
The full update note is available below.
MAIA Biotechnology January 2026 Update Note
Highlights from the note include:
- MAIA Biotechnology Raises $1.51 Million Through Private Placement with Continued Board Participation, Supporting Financial Runway and Highlighting Insider Conviction Ahead of Phase 3 Trial: MAIA Biotechnology announced the completion of a $1.51 million private placement through the issuance of 1,233,488 common shares at $1.224 per share, each accompanied by a warrant exercisable at $1.36 with a three-year term. Proceeds from the offering are intended to fund Step 1 of Part C of the Phase II THIO-101 trial and support general working capital as the company advances its clinical programs. Notably, independent directors participated in the financing, purchasing an aggregate 179,737 shares and an equal number of warrants, emphasizing continued insider alignment. Following the transaction, directors and officers collectively hold approximately 5.02 million shares, representing 13.43% ownership. We note that the successful placement, coupled with repeated insider participation, strengthens MAIA's near-term liquidity position and reflects sustained confidence in ateganosine's scientific differentiation and commercial potential, as the company progresses through pivotal Phase 3 development targeting advanced NSCLC.
- MAIA Initiates Pivotal Phase 3 THIO-104 Trial in Third-Line NSCLC, Marking Transition to Registrational Stage for Ateganosine: MAIA Biotechnology announced that the first patient has been dosed in its Phase 3 pivotal THIO-104 trial, a key inflection point as the ateganosine (THIO) program advances into a full registrational study in advanced non-small cell lung cancer (NSCLC). The multicenter, open-label trial will enroll up to 300 third-line NSCLC patients who are resistant to prior checkpoint inhibitor and chemotherapy regimens, randomizing patients 1:1 to ateganosine sequenced with a checkpoint inhibitor versus investigator's choice of chemotherapy, with overall survival as the primary endpoint. Regulatory approvals are in place to screen patients across Taiwan, Turkey, select EMA countries, and Georgia, with enrollment now underway. The initiation of THIO-104 builds directly on encouraging Phase 2 THIO-101 data, which demonstrated a median overall survival of 17.8 months, progression-free survival of 5.6 months (more than double standard-of-care chemotherapy), and individual patient survival extending to 30 months. Importantly, the company has disclosed a Bayesian assurance analysis for THIO-104, citing an estimated 96% probability of success at the interim analysis and a 99% probability of success at final analysis, based on the observed Phase 2 survival benefit and the trial's statistical design assumptions. Ateganosine's Fast Track designation from the FDA further supports an expedited regulatory pathway. From our perspective, first patient dosing in THIO-104 de-risks the development timeline, shifts the program into a value-defining phase, and positions MAIA for a potential comparative efficacy readout that could support full regulatory approval if Phase 2 benefits are confirmed at scale.
- Ateganosine Positioned as a Potential First-in-Class Telomere-Targeting Therapy Addressing a Critical Treatment Gap in Advanced NSCLC: MAIA Biotechnology outlined its view that the advanced non-small cell lung cancer (NSCLC) treatment landscape is approaching a strategic inflection point, particularly for patients without actionable mutations who have become refractory to checkpoint inhibitors (CPIs) and chemotherapy. While CPIs continue to dominate NSCLC treatment, accounting for an estimated $50 billion in global sales in 2024, their limitations in later-line settings leave a substantial unmet need. MAIA believes ateganosine represents a novel therapeutic class targeting telomerase activity, a near-universal feature of cancer cells, rather than mutation-specific or PD-1/PD-L1–dependent pathways. Supported by Fast Track designation from the FDA and the initiation of the Phase 3 THIO-104 trial, ateganosine is positioned to address this refractory patient population with a dual mechanism designed to induce direct cancer cell death while activating immune responses. From a commercial perspective, the NSCLC market is projected to grow from approximately $34 billion to $66 billion by 2032, and ateganosine's opportunity extends beyond lung cancer, with FDA Orphan Drug Designations already granted in glioblastoma, hepatocellular carcinoma, and small cell lung cancer. In our view, the convergence of clinical progress, regulatory momentum, and a differentiated mechanism places MAIA at a potentially pivotal juncture, where successful execution could establish telomere targeting as a new foundational approach in oncology.
About MAIA Biotechnology, Inc
Founded in 2018 and headquartered in Chicago, Illinois, MAIA is a biotechnology company engaged in discovering, developing, and commercializing novel cancer therapies with high unmet medical needs.
For more information, visit https://maiabiotech.com/
About Diamond Equity Research
Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on major institutional investor platforms.
For more information, visit https://www.diamondequityresearch.com.
Disclosures:
Diamond Equity Research LLC is being compensated by MAIA Biotechnology, Inc. for producing research materials regarding MAIA Biotechnology, Inc., and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however, the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for an annual or semi-annual research engagement. Diamond Equity Research LLC is being compensated by MAIA Biotechnology, Inc. for producing research materials regarding MAIA Biotechnology, Inc. and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for research engagement. As of 01/20/26, the issuer paid us $129,500 for research services, structured as follows: $20,000 for an initiation report and $15,000 for update notes in the first year; $20,000 for one update note and $11,500 for three follow-on notes in the second year; $20,000 for one update note and $11,500 for three follow-on notes in the third year; and $20,000 for one update note and $11,500 for three follow-on notes in the fourth year. Research services commenced and initiation payment was made on 11/10/22. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed $5,000. The issuer has not paid us for non-research-related services as of 01/20/26. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then. Although Diamond Equity Research company sponsored reports are based on publicly available information and although no investment recommendations are made within our company sponsored research reports, given the small capitalization nature of the companies we cover we have adopted an internal trading procedure around the public companies by whom we are engaged, with investors able to find such policy on our website public disclosures page. This report and press release do not consider individual circumstances and does not take into consideration individual investor preferences. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in small capitalization equities including the complete potential loss of their investment. Investors can find various risk factors in the initiation report and in the respective financial filings for MAIA Biotechnology, Inc. Please review update report attached for full disclosures.
Attachment
